Creative Medical Technology Holdings, Inc.
CELZHealthcare|Biotechnology|US
$0.62
+0.02 (+2.65%)
DCF Value
$2.94
Tangible Book / Share
$1.05
Cash / Share
$1.03
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05626712 Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes | Type 1 Diabetes, Diabetes Mellitus, Type 1 | P1P2 | Recruiting | 18 | RCT, Open-label | CELZ-201 Administration |
| NCT06053242 Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain | Chronic Low-back Pain, Degenerative Disc Disease | P1P2 | Active | 45 | RCT, Double-blind | CELZ-201-DDT |
| NCT07137559 CELZ-201-DDT for the Treatment of Chronic Lower Back Pain | Chronic Back Pain, Degenerative Disc Disease Lumbar | AVAILABLE | — | — | CELZ-201-DDT | |
| NCT07562243 Project PHOENIX: Molecular Signatures of Burn Pit Exposure | Burn Pit Exposure, Airborne Hazard Exposure | Not Yet Recruiting | 1,000 | — | — |